The effects of dose and method of administration of biosynthetic bovine somatotropin on live-weight gain, carcass composition and wool growth in young lambs

Lipid composition and metabolism of subcutaneous fat in sheep divergently selected for carcass lean content

Fatty acid synthetase and lipoprotein lipase activities, lipid content of adipose tissue and the fatty acid composition of subcutaneous fat, sampled by biopsy at the 13th rib, were measured in 20-week-old rams from lines of Texel-Oxford (TO) and Scottish Blackface (SB) sheep, both divergently selected for carcass lean content. A total of 150 animals were measured, with close to equal numbers of animals per selection line-breed combination.

In both breeds, the high (lean) selection lines had significantly lower backfat depths (TO : 0·5 mm and SB : 0·6 mm, s.e.d. 0·2) than the low (fat) lines. The lipid content of subcutaneous fat was 65 mg lipid per g fat tissue wet weight (s.e.d. 24) greater in TO rams than in SB rams. The TO low line had a higher lipid content than the high selection line (426 v. 448 (s.e.d. 36)) and although the SB selection lines did not differ, the selection line with breed interaction was not significant. SB rams had higher fatty acid synthetase activity (3·1 v. 2·6 (s.e.d. 0·3) on a log scale) but there were no differences between selection lines. Lipoprotein lipase activities were similar between breeds and selection lines. The lower concentration of myristic acid (C14:0) of TO rams compared with SB rams (0·9 (s.e.d. 0·3)) was the only breed or selection line difference which was statistically significant for fatty acid composition of subcutaneous fat.

Lipid content of subcutaneous fat and lipoprotein lipase activity were highly correlated and both were positively correlated with performance test traits, especially with backfat depth. The correlation between backfat depth and fatty acid synthetase activity was not different from zero. Performance test traits, lipid content of subcutaneous fat and lipoprotein lipase activity were positively correlated with the unsaturated fatty acids, with the exception of C18 :1 when correlations were negative.

Wool follicle development, wool growth and body growth in lambs treated from birth with recombinantly derived bovine somatotropin

The effect of recombinantly derived bovine somatotropin (bST) administration on wool follicle populations, wool growth and body growth was examined in young lambs. Romney × (Border Leicester × Romney) lambs were treated with bST at doses of 0·1 or 0·3 mg/kg live weight per day, or with excipient, commencing on the day of birth and continuing at weekly intervals until the last injection was given at 11 weeks of age. Concentrations of immunoreactive somatotropin in plasma were 19·2 (s.e. 2·1), 65·2 (s.e. 2·8) and 74·7 (s.e. 4·8) μgll in the control, low dose bST and high dose bST groups, respectively. Somatotropin treatment did not alter the density of primary (P) or secondary (S) follicles in the skin, or the S/P ratio, as measured by histological examination of mid-side skin biopsy samples at 14 weeks of age. Mid-side greasy and clean wool growth during weeks 2 to 14 of the study were increased (P < 0·05) in bST-treated lambs but treatment had no effect on wool growth during the immediate post-treatment period (weeks 14 to 22), or on yearling fleece weight or wool quality characteristics. Body growth was not altered by bST administration. It is concluded that bST treatment stimulates wool growth even in very young lambs but, contrary to the results of a previous study, does not alter the development of wool follicle populations.

Effects of recombinant DNA-derived bovine somatotropin on growth, carcass characteristics and meat quality in lambs from three breeds

Purebred lambs from three breeds (East Friesland, Oxford and Texel) were fed to appetite and treated with recombinant DNA-derived bovine somatotropin (BST) at 0·05, 0·10 or 0·20 mg/kg per day or a placebo between 19 and 27 weeks of age.

BST maintained growth over the later stages of treatment but did not affect average daily live-weight gain over the whole treatment period. Food intake was decreased and food conversion efficiency was improved by BST treatment. However, carcass weight and killing-out proportion were decreased by BST treatment in all breeds. Consistent breed differences were observed. Oxford lambs had higher live weights and carcass weights than the other breeds but no breed × treatment interactions were apparent. Ultrasonic backfat depth (mean of measurements at 13th rib and 3rd lumbar vertebra) was reduced by BST treatment in the Oxford (the fattest) and Texel lambs but not in the East Frieslands (the leanest). Ultrasonic muscle depth was not affected by BST; East Friesland lambs had considerably smaller muscle depth than the other breeds.

In the loin joint, BST decreased fat cover and subcutaneous fat proportion and increased longissimus dorsi proportion. There were also marked breed differences with Oxfords fatter than the other breeds. BST treatment did not affect any of the meat quality indicators but some differences between breeds were apparent in ultimate pH and colour of the muscle. Fatty acid composition of the subcutaneous fat was affected by breed but not by BST. East Friesland lambs had higher concentrations of unsaturated and branched chain fatty acids than the other breeds.

A mammogenic response (increased mammary development and some secretory activity) to BST was observed in some female East Friesland and Texel lambs but not in Oxford lambs.

The effects of short-term recombinant bovine somatotropin treatment on fattening performance, carcass composition and visceral organ weights in karayaka lambs in Turkey

Recombinant bovine somatotropin (bST) was administered s.c. to lambs for 6 weeks to evaluate its effects on fattening performance, carcass composition and visceral organ weights. Twenty male Karayaka lambs were injected with 250 mg bST every two weeks. Body weight, live weight gain, feed intake and feed conversion rate were not affected by treatment. Head, feet, skin, liver, spleen, kidneys, filled and empty gastrointestinal tract, penis, testis, pelvic fat and internal fat weights were similar for the two groups. Lung weight increased by 17.4% (P<0.01) and weight of heart decreased 22.7% (P<0.05) in bST treated lambs. The only carcass characteristics that were affected by bST administration were limb muscle which increased from 1331 g to 1417 g (P<0.05), loin fat which decreased from 275 g to 174 g (P<0.01), shoulder fat which decreased from 26 g to 13 g (P<0.01) and total fat/final weight percentage which decreased from 9.8% to 7.6% (P<0.05). The results of this study show that prolonged release formulation of bST treatment reduces fat tissue, but does not significantly affect fattening performance or weights of visceral organs, muscle and bone.

Recombinant human growth hormone modifies the inherent partition of nutrients in growing female and male BALB/c mice

BALB/c mice weaned at 21 days were used to investigate the effects of exogenous recombinant human growth hormone (rhGH) administration on the growth performance and carcass composition in females and males allowed to consume feed ad libitum. Forty mice were assigned within each sex (female [F] and male [M] to treatment of either 20 microL g-1 saline (Fs and Ms groups) or 74 ng rhGH g-1 body weight (BW) in 20 microL saline (FGH and MGH groups). At 50 d of age the mice were weighed and then killed by cervical dislocation. Treatment with rhGh improved feed conversion only in growing female mice by enhancing weight gain relative to feed protein intake and weight growth rate without modification of feed consumption, according to a multiple comparison test (LSD). Ms mice showed less carcass fat gain (162%), less fat accretion rate (129%), higher carcass water gain (12%) and higher water accretion rate (28%) than Fs mice. The administration of rhGH modified this distribution inducing an increase in gain and accretion rates of protein (34%), water (41%) and ash (33%) and a reduction in gain and accretion rate of fat (50%) in FGH mice, and only an increase of gain (91%) and accretion rate of fat (67%) in MGH mice compared to saline mice. As result, a decrease in protein gain:fat gain ratio of MGH mice compared to FGH (34%) and Ms (63%) mice was elicited by rhGH, inverting the inherent sexual propensity for fat and protein deposition in growing male mice, due to GH, sex, and to GH x sex interaction influence.

Improved wool production in transgenic sheep expressing insulin-like growth factor 1

Transgenic sheep were produced by pronuclear microinjection with a mouse ultra-high-sulfur keratin promoter linked to an ovine insulin-like growth factor 1 (IGF1) cDNA. Five transgenic lambs resulted from the microinjection of 591 embryos; one male and one female showed IGF1 expression in the skin. A progeny test of the ram was carried out by matings to 43 non-transgenic ewes. Of 85 lambs born, 43 (50.6%) were transgenic. At yearling shearing (approximately 14 months of age), clean fleece weight was on average 6.2% greater in transgenic animals than in their non-transgenic half-sibs, with a greater effect in males (9.2%) than females (3.4%). Transgenics showed a small but significant increase in bulk, but male transgenics had a lower staple strength than female transgenics and non-transgenics which did not differ significantly. There were no significant differences in fiber diameter, medullation, and hogget body weight. To our knowledge this is the first reported improvement in a production trait by genetic engineering of a farm animal without adverse effects on health or reproduction.

Growth, body composition, hormonal and metabolic status in lambs treated long-term with growth hormone

The effect of long-term (10 weeks) treatment with growth hormone (GH) was investigated in twin lambs, one sibling being a control and the other treated with GH (0.1 mg/kg live weight per d). The lambs were fed on a concentrate-grass cube (9:1 w/w) diet at a daily rate of 40 g fresh weight/kg live weight. The average daily live-weight gain of the GH-treated lambs was 36% greater than that of the controls (307 v. 225 g/d, P less than 0.01). The carcass composition of the GH-treated lambs changed: fat content was decreased (P less than 0.01) and protein content was increased (P less than 0.05) when expressed relative to carcass dry matter. The absolute weights and the weights when expressed relative to fleece-free empty body of some muscles were significantly increased in GH-treated lambs. The mean retention times of both particulate- and liquid-phase components of the digesta were unchanged by GH treatment, when calculated for the rumen or for the entire gastrointestinal tract. The feed conversion ratio was significantly greater (P less than 0.01) in GH-treated lambs compared with controls. Nitrogen retained per g N intake was also significantly increased (P less than 0.05) by GH treatment. Plasma urea concentrations were decreased (P less than 0.05) and glucose concentrations were increased (P less than 0.01) in GH-treated lambs, whereas non-esterified fatty acid concentrations were unchanged. Plasma insulin and total insulin-like growth factor-1 concentrations progressively increased in GH-treated lambs as treatment time continued. They were significantly correlated after week 4 of treatment. Two types of hepatic GH-binding site were detected, with high and low affinities for GH. The capacities of both binding sites were significantly increased (P less than 0.05) in GH-treated lambs when expressed per unit microsomal protein but, when expressed per liver, only the capacity of the high-affinity site was increased.

Effect of immunization against somatostatin in the pregnant ewe on growth and endocrine status of the neonatal lamb

Absorption of somatostatin (SRIF) specific antibodies from colostrum of ewes actively immunized against SRIF may improve growth rate of the neonatal lamb by neutralizing the inhibitory effects of SRIF on pituitary and thyroid function. Growth and endocrine parameters in the offspring of SRIF immunized (SI) and control (C) crossbred ewes were examined. Lamb weight was recorded at birth and twice each week to 24 days of age. Blood samples were collected prior to first suckle and twice each week. At 21 to 24 days of age, in separate experiments, lambs were infused with glucose (0.29 g/kg), arginine (0.25 g/kg) or thyrotropin-releasing hormone (TRH; 0.33 microgram/kg). A strong correlation (R = 0.88; P less than .01) was observed between anti-SRIF titre in the ewe at parturition and in the lamb at 3 days of age. No effect on lamb birth weight (SI 4.28 +/- 0.27 kg; C 4.35 +/- 0.23 kg) was observed. At 24 days of age cumulative gain in SI lambs (5.4 +/- 0.32 kg) was greater (P less than .05) than in C lambs (4.5 +/- 0.32 kg). The growth hormone secretory responses to glucose or arginine were not affected by treatment. Plasma IGF-I, plasma thyroxine (T4) and the plasma thyrotropin and T4 responses to TRH were not different between treatments. Plasma triiodothyronine (T3) was higher (P less than .05) in SI (2.46 +/- .10 ng/ml) than in C (2.01 +/- .05 ng/ml) lambs, however, the plasma T3 response to TRH was lower in SI lambs. Plasma glucose (mg/dl) was higher (P less than .05) in SI (118.4 +/- 1.7) than in C (106.0 +/- 4.0) lambs. Plasma insulin was not affected by treatment. Increased plasma T3 and glucose concentrations during SRIF immunoneutralization in the neonate lamb may be important factors contributing to the growth response observed.

Antilipogenic but not lipolytic effects of recombinant DNA-derived bovine somatotropin treatment on ovine adipose tissue; variation with genetic type

1. Lambs from three breeds (East Friesland, Oxford and Texel) were treated with recombinant DNA-derived bovine somatotropin (BST) at 0.05, 0.10, 0.20 mg/kg per day and fat metabolism assessed in subcutaneous adipose tissue biopsy samples. 2. BST treatment decreased adipose cell volume, fatty acid synthesis and acylglycerol glycerol synthesis but did not alter lipolytic rates (basal or noradrenaline-stimulated). 3. Genetic type influenced metabolism in a number of ways, most notably East Friesland lambs had lower fatty acid esterification rates and responded poorly to BST in terms of reduced lipogenesis as compared to the Oxford and Texel lambs. 4. Blood urea concentration was decreased by BST treatment suggesting increased nitrogen retention. 5. These results emphasise the role of somatotropin as an inhibitor of adipose tissue lipogenesis but cast further doubt on a physiological role in regulating lipolysis.